/PRNewswire/ Following the successful filing of Intellectual Property (IP) for their applied platform technology targeting the endocannabinoid system (ECS),.
/PRNewswire/ Following convincing results from a recent In-Vitro study, the Danish biotech company, Tetra Pharm Technologies, today announces successful.
/PRNewswire/ Located approx. 40 kilometers north of Copenhagen firmly within Medicon Valley – the leading international life science cluster spanning the.
/PRNewswire/ In a recent In-Vitro study of TPT0301, Tetra Pharm Technologies s novel drug delivery technology was compared against more commonly utilized.
/PRNewswire/ Tetra Pharm Technologies develops and manufactures pharmaceutical drugs targeting the endocannabinoid system for the treatment of neuropathic.